Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Tomaschitz, A; Piecha, G; Ritz, E; Meinitzer, A; Haas, J; Pieske, B; Wiecek, A; Rus-Machan, J; Toplak, H; März, W; Verheyen, N; Gaksch, M; Amrein, K; Kraigher-Krainer, E; Fahrleitner-Pammer, A; Pilz, S.
Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications.
Clin Exp Hypertens. 2015; 37(2):108-115
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Amrein Karin
Fahrleitner-Pammer Astrid
Gaksch Martin
Haas Josef
Maerz Winfried
Meinitzer Andreas
Pieske Burkert Mathias
Pieske-Kraigher Elisabeth
Pilz Stefan
Tomaschitz Andreas
Toplak Hermann
Verheyen Nicolas Dominik

Dimensions Citations:

Plum Analytics:
The cardiotonic steroid marinobufagenin (MBG) is increasingly suggested to be responsible for some of the cardiovascular injury that has been previously attributed to aldosterone. We examined the clinical correlates of circulating MBG concentrations in hypertensive patients and tested the hypothesis that MBG serves as a reliable diagnostic tool for detecting primary aldosteronism (PA). Plasma MBG concentrations (mean: 0.51±0.25 nmol/l) were measured in the morning fasting samples in 20 patients with PA and 20 essential hypertensive (EH) controls matched for age, sex, body mass index, renal function, urinary sodium and intake of antihypertensive medication (mean age: 51.6 years; 52.2% women). Overall, plasma MBG was directly correlated with plasma aldosterone, aldosterone to active renin ratio (AARR), diastolic blood pressure, mean carotid intima-media thickness, serum sodium, urinary protein to creatinine ratio and inversely with serum potassium levels. Plasma MBG levels were significantly higher in patients with PA compared to EH (mean: 0.68±0.12 versus 0.35±0.24 nmol/l; p<0.001). ROC analysis yielded a greater AUC for plasma MBG compared to the AARR, PAC and serum potassium levels for detecting PA. Youden's Index analyses yielded the optimal plasma MBG cut-off score for diagnosing PA at >0.49 nmol/l with specificity and sensitivity values of 0.85 and 0.95, respectively, which were higher than those at the optimum AARR cut-off at >3.32 ng/dl/µU/ml. In a well-characterized cohort, values of plasma MBG were significantly related to clinical correlates of cardiovascular and renal disease. Plasma MBG emerged as a valuable alternative to the AARR for screening of PA.
Find related publications in this database (using NLM MeSH Indexing)
Aldosterone - blood
Blood Pressure - drug effects
Bufanolides - pharmacokinetics Bufanolides - therapeutic use
Carotid Intima-Media Thickness -
Female -
Follow-Up Studies -
Humans -
Hyperaldosteronism - blood Hyperaldosteronism - drug therapy Hyperaldosteronism - physiopathology
Hypertension - blood Hypertension - drug therapy Hypertension - physiopathology
Male -
Middle Aged -
Renin - blood
Retrospective Studies -
Treatment Outcome -
Vasoconstrictor Agents - pharmacokinetics Vasoconstrictor Agents - therapeutic use

Find related publications in this database (Keywords)
primary aldosteronism
© Meduni Graz Impressum